Norfolk Product Liability Lawyer Report: FDA Claims Diabetes Drug, Actos Increases Risk for Bladder Cancer
Actos (pioglitazone) was one of the top drugs used to help control blood sugar levels for patients with Type 2 diabetes whose condition is not sufficiently controlled by diet and exercise alone. Takeda Pharmaceuticals is the manufacturer of Actos, released this drug to the American market in 2011.
The US Food and Drug Administration (FDA) discovered a link between bladder cancer and Actos. A FDA study discovered a link had been found for patients who took Actos for more than 24 months. Actos comes in 15, 30 and 45 mg tablets. The risk of bladder cancer was also increased with people who took higher dosages.
The FDA conducted a study using side effect reports from more than 500,000 diabetics who were on Actos or other medication. More than 1/5 of those involving bladder cancer occurred with patients on Actos.
In 2011, the FDA issued a warning that even just one year on Actos raises the risk of bladder cancer by more than 40%. The FDA is advising doctors not prescribe Actos to patients with bladder cancer and to closely monitor its use with patients already suffering from bladder cancer.
Countries in Europe like France and Germany have pulled Actos from the market for safety precautions regarding bladder cancer.
Patients take drugs to make them feel better, to ease their lives. This is unacceptable for a drug to have such dire side effects. The maker of this drug is to blame. Takeda Pharmaceuticals should have done more research before release such a toxin to the public. If you or a loved one has been diagnosed with bladder cancer after taking Actos for more than one year, you may be able to seek compensation for financial and physical suffering.